"Green light" from the UK for the booster dose of the Pfizer/BioNTech vaccine Encouraging clinical trial results
The regulatory authority in the UK today (3/9) approved the booster dose of Pfizer/BioNTech's COVID-19 bivalent vaccine for children over 12 years of age and older.
According to the same agency (The Medicines and Healthcare products Regulatory Agency), the decision was based on evidence from a clinical study showing that the booster dose with the Pfizer/BioNTech vaccine pair induces a strong immune system response against both the Omicron variant and the original strain.
Commission calls for coordination of efforts for autumn and winter
At the same time, the European Commission is proposing concrete measures to avoid an increase in coronavirus cases in the coming autumn and winter season.
The Commission urges Member States to put in place the necessary strategies and structures, including vaccination and surveillance against COVID-19, to respond to future outbreaks in a rapid and sustained manner.
The main objective of the actions proposed by the Commission is to increase the uptake of vaccines, including adapted and new vaccines, and to ensure that all citizens are well protected.
"The last two years have prepared the EU to face another wave of COVID-19 this autumn and winter," said Vice President for the Promotion of the European Way of Life, Margaritis Schinas.
Furthermore, he added that the actions of the European Union will determine the future of the pandemic.
"Member States should continue to coordinate preparedness efforts across the EU in view of the next wave and the further development of vaccination programmes. Taking action now will reduce pressure on healthcare systems, disruption to economies and challenges to society."
Source.gr
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source